CoChat

Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond

Klempner, Samuel J., Hata, Aaron N. · 2020 · Cancer Discovery

The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.

Abstract

Summary: Hallin and colleagues demonstrate the preclinical activity of the KRASG12C-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. Variable responsiveness despite effective KRASG12C inhibition highlights both the promise and potential need for combinatorial strategies to optimally target KRASG12C-driven cancers. See related article by Hallin et al., p. 54.

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-1255

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 9 references

Cited by

See all 15

Metadata

Authors
Klempner, S. J., & Hata, A. N.
Affiliations
Harvard University (US)
Venue
Cancer Discovery
Published
2020-01-01
Volume
10
Issue
1
Pages
20-22
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2999411977
Cited by
15
References
10
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 6 · 2020: 4
FWCI
1.05
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
KRAS G12C, KRAS inhibitors, adagrasib, KRAS-driven cancers, combination therapy, drug resistance, targeted cancer therapy
MeSH terms
Animals, Antineoplastic Agents, Disease Models, Animal, Humans, Mutation, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-1255
The paper
Klempner, S. J., & Hata, A. N. (2020). Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-1255

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.